Literature DB >> 1778701

Economic analysis alongside clinical trials. Revisiting the methodological issues.

M F Drummond1, L Davies.   

Abstract

Controlled clinical trials are recognized as the best source of data on the efficacy of health care interventions and technologies. Because economic evaluation is dependent on the quality of the underlying medical evidence, clinical trials have increasingly been viewed as a natural vehicle for economic analysis. However, the closer integration of economic and clinical research raises many methodological issues. This paper discusses these issues in trial design, collection of resource use data, collection of outcome data, and interpretation and extrapolation of results. Some guidelines are suggested for economic analysts wishing to undertake evaluations alongside clinical trials.

Mesh:

Year:  1991        PMID: 1778701     DOI: 10.1017/s0266462300007121

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  77 in total

Review 1.  Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

Authors:  C Bombardier; A Maetzel
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.

Authors:  D A Revicki; L Frank
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

3.  Challenges to the economic evaluation of new biotechnological interventions in healthcare.

Authors:  J Mason
Journal:  Pharmacoeconomics       Date:  1999-08       Impact factor: 4.981

4.  Randomized controlled trial and economic evaluation.

Authors:  S Jain; N K Arora
Journal:  Indian J Pediatr       Date:  2000-05       Impact factor: 1.967

5.  Using economic evaluations to reduce the burden of asthma and chronic obstructive pulmonary disease.

Authors:  M Sculpher
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

6.  Economic analysis of randomized, controlled trials.

Authors:  G H Lyman
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 7.  Modelling in health economic evaluation. What is its place? What is its value?

Authors:  A Brennan; R Akehurst
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 8.  Testing the validity of cost-effectiveness models.

Authors:  C McCabe; S Dixon
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

9.  The problem of protocol driven costs in pharmacoeconomic analysis.

Authors:  D Coyle; K M Lee
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

Review 10.  The role of cost-effectiveness analysis in managed-care decisions.

Authors:  H Grabowski
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.